Dmitry Balyasny Balyasny Asset Management
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPCX
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
CTRA
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.69% |
| 2 | Industrials | 9.96% |
| 3 | Consumer Discretionary | 8.03% |
| 4 | Healthcare | 7.46% |
| 5 | Financials | 6.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
PUT
American Express
AXP
$227B
| $14.8M | 0.02% |
43,700
+4,500
| +11% | +$1.44M |
|
827
Imperial Oil
IMO
$66.8B
| $14.8M | 0.02% |
131,539
+127,638
| +3,272% | +$16M |
|
828
Chewy
CHWY
$9.83B
| $14.8M | 0.02% |
751,174
-600,270
| -44% | -$13.6M |
|
829
PUT
Kinder Morgan
KMI
$69B
| $14.8M | 0.02% |
461,400
+74,300
| +19% | +$2.39M |
|
830
Hertz
HTZ
$802M
| $14.7M | 0.02% |
6,505,105
+4,487,472
| +222% | +$24.5M |
|
831
Viavi Solutions
VIAV
$9.6B
| $14.7M | 0.02% |
308,561
-136,518
| -31% | -$6.54M |
|
832
Zegna
ZGN
$3.73B
| $14.7M | 0.02% |
1,131,031
+576,398
| +104% | +$7.43M |
|
833
Pultegroup
PHM
$24.6B
| $14.7M | 0.02% |
107,295
-506,375
| -83% | -$61.5M |
|
|
ESPR
834
DELISTED
Esperion Therapeutics
ESPR
| $14.7M | 0.02% |
+4,654,778
| New | +$13M |
|
835
RenaissanceRe
RNR
$13.4B
| $14.7M | 0.02% |
+46,380
| New | +$13.9M |
|
836
Motorola Solutions
MSI
$79.5B
| $14.7M | 0.02% |
35,351
-285,069
| -89% | -$119M |
|
837
ScottsMiracle-Gro
SMG
$3.55B
| $14.7M | 0.02% |
215,537
+138,931
| +181% | +$8.61M |
|
838
SAB Biotherapeutics
SABS
$344M
| $14.7M | 0.02% |
3,760,439
| – | – |
|
839
Prime Medicine
PRME
$615M
| $14.6M | 0.02% |
3,969,082
-154,283
| -4% | -$512K |
|
|
ZBIO
840
Zenas BioPharma
ZBIO
$2.1B
| $14.6M | 0.02% |
576,717
-90,353
| -14% | -$1.8M |
|
841
NextDecade
NEXT
$1.9B
| $14.5M | 0.02% |
1,926,956
-613,199
| -24% | -$4.85M |
|
842
Ares Capital
ARCC
$14.3B
| $14.5M | 0.02% |
783,779
-9,930
| -1% | -$185K |
|
843
PUT
Booking.com
BKNG
$158B
| $14.5M | 0.02% |
81,400
-6,100
| -7% | -$1.04M |
|
844
PUT
BILL Holdings
BILL
$4.76B
| $14.5M | 0.02% |
400,000
-875,000
| -69% | -$32.2M |
|
845
Cousins Properties
CUZ
$4.89B
| $14.4M | 0.02% |
481,192
+358,437
| +292% | +$9.4M |
|
846
Sylvamo
SLVM
$1.46B
| $14.4M | 0.02% |
380,881
+359,687
| +1,697% | +$14.6M |
|
|
TRAX
847
First Tracks Biotherapeutics
TRAX
$1.54B
| $14.4M | 0.02% |
+714,948
| New | +$13.4M |
|
848
Revolve Group
RVLV
$1.69B
| $14.4M | 0.02% |
627,133
-571,915
| -48% | -$12.7M |
|
849
Helmerich & Payne
HP
$4.35B
| $14.4M | 0.02% |
+438,367
| New | +$16.4M |
|
850
CALL
United Parcel Service
UPS
$86.8B
| $14.3M | 0.02% |
133,200
+120,300
| +933% | +$12.5M |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $7.14B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Technology at 13% of assets, up from 9.7% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.